Journal of Advanced Research in Health Sciences 2651-4060 Istanbul University 10.26650/JARHS2025-1606937 Chest Diseases Clinical Chemistry Clinical Oncology Göğüs Hastalıkları Klinik Kimya Klinik Onkoloji CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER? LYVE-1 MOLEKÜLÜ İLERİ EVRE AKCİĞER KANSERLİ HASTALARDA TANISAL BİR BİYOBELİRTEÇ OLABİLİR Mİ? https://orcid.org/0000-0001-8502-2505 Serilmez Murat İstanbul University, Oncology Institute, Department of Basic Oncology https://orcid.org/0000-0002-4995-4759 Özgür Emre İstanbul University, Oncology Institute, Department of Basic Oncology https://orcid.org/0000-0002-7858-1584 Oğuz Soydinç Hilal İstanbul University, Oncology Institute, Department of Basic Oncology https://orcid.org/0000-0002-8732-4117 Tilgen Yasasever Ceren İstanbul University, Oncology Institute, Department of Basic Oncology https://orcid.org/0000-0001-6514-7116 Taş Faruk İstanbul University, Oncology Institute, Department of Clinic Oncology https://orcid.org/0000-0001-8471-5254 Gezer Uğur İstanbul University, Oncology Institute, Department of Basic Oncology https://orcid.org/0000-0002-2820-3227 Duranyıldız Hadiye Derya İstanbul University, Oncology Institute, Department of Basic Oncology 03 04 2025 8 1 7 14 12 25 2024 02 10 2025 Copyright © 2018, Journal of Advanced Research in Health Sciences 2018 Journal of Advanced Research in Health Sciences

Objective: Primary lung cancers that originate from epithelial cells are classified as carcinomas. Close monitoring of patients with predisposing conditions can enhance early diagnosis rates and facilitate the implementation of therapeutic approaches. LYVE-1 protein is localized to the lymphatic endothelial layer. This study aimed to evaluate the clinical utility of the serum protein and circulating mRNA of LYVE-1 in lung cancer.Materials and Methods: We performed ELISA and Real-time PCR to measure and compare the serum protein and circulating mRNA levels of LYVE-1 in the peripheral blood of 60 patients with advanced lung cancer and 20 controls.Results: Serum LYVE-1 protein and gene expression levels were significantly higher in patients with lung cancer than in controls (p=0.001). There was no association between LYVE-1 (both protein and gene) clinical parameters. The outcome of the ROC analysis, serum LYVE-1 protein (AUC: 0.873) or LYVE-1 gene (AUC: 0.921) in lung cancer patients.Conclusion: As far as we are aware, this study represents the first investigation to compare the protein and mRNA levels of LYVE-1 in the blood samples of lung cancer patients. Additional research involving a larger cohort of subjects will be necessary to gain a deeper understanding of the mechanisms and consequences of LYVE-1 inhibitors in lung cancer.

Amaç: Primer akciğer kanserleri epitelyal hücrelerden türeyen karsinom lardır. Predispozan bozukluğu olan hastaların yakın takibi, erken tanı ve küratif tedavi yöntemlerinin oranlarında artış sağlayabilir. Hyaluronan için bir reseptör molekülü olan LYVE-1, lenfatik endotelde ifade edilir. Bu çalış ma, akciğer kanserinde LYVE-1’in serum proteini ve dolaşımdaki mRNA’sının klinik faydasını değerlendirmeyi amaçlamıştır. Gereç ve Yöntemler: İleri evre 60 akciğer kanseri hastası ve 20 sağlıklı kontrolün periferik kanında LYVE-1’in serum protein ve dolaşımdaki mRNA seviyelerini ölçmek ve karşılaştırmak için ELISA ve Gerçek Zamanlı PCR uygulaması gerçekleştirildi.Bulgular: Akciğer kanserli hastalarda serum LYVE-1 protein ve gen ekspres yon düzeyleri kontrol grubuna göre anlamlı derecede yüksek bulunmuştur (p=0,001). Akciğer kanseri hastalarında serum LYVE-1 protein ve gen eks presyon düzeyleri ile klinik parametreler arasında bir ilişki bulunmamıştır. ROC analizine göre eğri altında kalan alanlar hesaplandığında; serum LYVE 1 proteini ve geni için AUC (Area Under Curve) değerleri sırasıyla 0,873, 0,921 şeklinde bulunmuştur.Sonuç: Bu çalışma, akciğer kanseri hastalarının kan örneklerinde LYVE-1’in protein ve mRNA düzeylerini karşılaştıran ilk çalışmadır. Akciğer kanserin de LYVE-1 inhibitörlerinin mekanizmalarını ve sonuçlarını daha derinleme sine anlamak için daha geniş bir denek grubunu içeren ek araştırmalara ihtiyaç duyulmaktadır. Bu tür araştırmalar, bu alana ilişkin değerli bilgiler sağlamada faydalı olacaktır.

 LYVE-1 lung cancer lymphatic biomarker YVE-1 akciğer kanseri lenfatik biyomarker Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. google scholar Yilmaz S, Dogan Sarikaya M, Yasar E, Sen Burcu B, Canoz O, Onal O. determination of metastatic capacity in primary lung cancer cells: reflection of patient profile in the clinic using in vitro methods. Journal of Advanced Research in Health Sciences 2023;6(3):302-11. google scholar Witte MH, Witte CL. Lymphatics and blood vessels, lymphangiogenesis and hemangiogenesis: from cell biology to clinical medicine. Lymphology 1987;20(4):257-66. google scholar Gerli R, Solito R, Weber E, Agliano M. Specific adhesion molecules bind anchoring filaments and endothelial cells in human skin initial lymphatics. Lymphology 2000;33(4):148-57. google scholar Ryan TJ. Structure and function of lymphatics J Invest Dermatol (Suppl) 1989;93:18-24. google scholar Skobe M, Detmar M. Structure, function, and molecular control of the skin lymphatic system. J Invest Dermatol Symp Proc 2000;5:14-9. google scholar Von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3(11):867-78. google scholar Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2(8):573-83. google scholar Oliver G, Sosa-Pineda B, Geisendorf S, Spana EP, Doe CQ, Gruss P. Prox1, a prospero-related homeobox gene expressed during mouse development. Mech Dev 1993.44(1):3-16. google scholar Nakamura K, Rockson SG. Biomarkers of lymphatic function and disease. Mol Diag Ther 2007;11(4):227-38. google scholar Wigle, JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999;98(6):769-78. google scholar Banerji S, Ni J, Wang SX, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789-801. google scholar Prevo R, Banerji S, Ferguson D, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronanin lymphatic endothelium. J Biol Chem 2001;276:19420-30. google scholar Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003;13:1-7. google scholar Dhama K, Latheef SK, Dadar M, Samad H, Munjal A, Khandia R, et al. Biomarkers in stress related diseases/disorders: diagnostic, prognostic, and therapeutic values. Front Mol Biosci 2019;18:691. google scholar Wishart DS, Bartok B, Oler E, Liang KY, Budinski Z, Berjanskii M, et al. An online database of molecular biomarkers. Nucleic Acids Res 2021;49:D1259-67. google scholar Jauch AS, Wohlfeil SA, Weller C, Dietsch, V, Stojanovic A, Kittel M, et al. Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis Cancer Cell Int 2022;22(1):398. google scholar Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, et al. Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen. Immunity 2018;49(6):1191. google scholar Fujimoto A, Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Maehara S, et al. Significance of lymphatic invasion on regional lymph node metastasis in early gastric cancer using LYVE-1 immunohistochemical analysis. J Clin Pathol 2007;127:82-8. google scholar Wrobel T, Dziegiel P, Mazur G, Zabel M, Kuliczkowski K, Szuba A. LYVE-1 expression on high endothelial venules (HEVs) of lymph nodes. Lymphology 2005;38:107-10. google scholar Carreira CM, Nasser SM, Tomaso E, Padera TP, Boucher Y, Tomarev SI, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001;61:8079-84. google scholar Ozmen F, Ozmen M, Ozdemir EM, Moran M, Seçkin S, Guc D, et al. Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer. World J Gastroenterol 2011;17:3220-8. google scholar Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2005;58:202-6. google scholar Nunomiya K, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, et al. Relationship between serum level of lymphatic vessel endothelial hyaluronan receptor-1 and prognosis in patients with lung cancer J. Cancer 2014;5(3):242-7. google scholar Yoo YA, Kang MH, Lee HJ, Kim B, Park JK, Kim HK, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res 2011;71(22):7061-70. google scholar Prevo R, Banerji S, Ferguson DJ, Clasper DS, Jackson DK. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. JBC Papers in Press 2001;276(22):19420-30. google scholar Nunomiya K, Shibata, Abe S, Inoue S, Igarashi A, Yamauchi K, et al. Relationship between serum level of lymphatic vessel endothelial hyaluronan receptor-1 and prognosis in patients with lung. Cancer J Cancer 2014;5(3):242-7. google scholar Du Y, Liu H, He Y, Liu Y, Yang C, Zhou M, et al. The interaction between LYVE-1 with hyaluronan on the cell surface may play a role in the diversity of adhesion to cancer cells. PLoS One 2013;8(5). google scholar Shibata MA, Hamaoka H, Kanayama T, Maemura K, Ito Y, Linuma M, et al. Synthetic a-mangostin dilaurate strongly suppresses widespectrum organ metastasis in a mouse model of mammary cancer. Cancer Sci 2018;109(5):1660-71. google scholar PenG LI, Cong Z, Yong Qiang, Lei Xiong, Tang L, Zhang Y, et al. Significance of CCBE1 expression in lung cancer. Mol Med Rep 2018;17(2):2107-12. google scholar